Treating Hepatitis C Virus Infection in Active Substance Users
Open Access
- 15 April 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (s5) , S321-S324
- https://doi.org/10.1086/427447
Abstract
Although injection drug users represent the majority of new and existing cases of infection with hepatitis C virus (HCV), many lack access to treatmeKeywords
This publication has 9 references indexed in Scilit:
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Treating hepatitis C in methadone maintenance patients: an interim analysisDrug and Alcohol Dependence, 2002
- Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-UpEuropean Addiction Research, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Hepatitis C Virus InfectionNew England Journal of Medicine, 2001
- Treatment of Hepatitis C Infection in Injection Drug UsersHepatology, 2001
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusPublished by Elsevier ,1998
- The Importance of Preventing Hepatitis C Virus Infection Among Injection Drug Users in the United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998